Moderna to keep testing flu shot as it fails to meet 'early success' criteria

Data from the second trial comes two months after its flu vaccine generated a strong immune response against influenza A strains, but was inferior to an approved vaccine when compared to the less-prevalent influenza B strain in the first late-stage study. Moderna also forecast sales from its respiratory vaccines to be between $8 billion and $15 billion in 2027. It is testing vaccines against respiratory syncytial virus (RSV), influenza and a next-generation COVID-19 shot in late-stage studies.

from Industry-Economic Times https://ift.tt/C6Qa0eg
via IFTTT